MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Met Syn Lysine Ltd.
Met Syn Lysine Ltd.

In individuals with Obesity/Metabolic Syndrome, there is a chronic elevation of blood Insulin levels, which in turn increases Insulin Resistance, causing an increase in appetite and over-eating, thus creating a vicious cycle.
We will cut-off this vicious cycle by inhibiting the Insulin secretion, and reducing it, using an analogue of the hormone Somatostain which naturaly inhibits Insulin after a meal.
There is a clear-cut correlation between inhibiting Insulin secretion and weight loss.
Cyclic oral Somatostatin analogue to reverse the Metabolic Syndrome will lower weight, blood sugar(Diabetes),lipids & blood pressure.

Connect with Met Syn Lysine Ltd.

2020

2020 Finalist Israel

Sub industry

Therapeutics (Pharma / Biotech)

Mission

MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.